Science Corporation Implants PRIMA Retinal Chip in First Stargardt Patient
Max Hodak advances neural engineering through commercial vision restoration implants.
1PRIMA Enters Clinical Stargardt Trial
Science Corporation announced the successful implantation of its PRIMA vision-restoration chip into its first Stargardt disease patient. The surgical procedure took place in May at the Sydney Eye Hospital in Australia. This milestone marks the expansion of PRIMA beyond geographic atrophy into incurable inherited central vision loss conditions.
2Rapid Visual Recovery Post-Implant
The patient demonstrated functional progress during initial clinical rehabilitation sessions. In the first session, the patient successfully identified an individual letter, progressing to reading a full word during the second session. These functional results validate the device's capacity to relay legible high-contrast visual signals directly to the intact inner retina.
3Two-Millimeter Subretinal Hardware Architecture
The PRIMA system relies on a two-millimeter square chip surgically placed beneath the degenerated photoreceptor layer. External camera-equipped glasses capture environmental imagery and project processed data directly onto the implant. The subretinal microchip converts these signals into electrical impulses, functioning effectively as an artificial replacement for damaged photoreceptors.
4Monochrome Central Visual Acuity
The current generation implant provides high-contrast, black-and-white visual perception within a narrow central field of view. Max Hodak described the present experience as looking through a straw. The device prioritizes sharpness over wide angles, allowing patients to read several high-contrast letters simultaneously rather than processing full-color visual scenes.
5Roadmap Toward Native Resolution
Engineering teams are currently developing next-generation hardware scheduled for human clinical trials within the next year. Future iterations aim to expand field-of-view by conforming to ocular curvature while reducing electrode size. Hodak expects these structural micro-electrode refinements to approach native visual acuity within the next five years.
6Strategic BCI Commercialization Path
Unlike pure software interfaces, Science Corporation uses retinal prosthetics to build a viable clinical pipeline before deploying broader brain-computer interfaces. Since the retina forms part of the central nervous system, restoring sensory pathways provides immediate commercial validation while advancing foundational neural engineering methods across practical neurotechnology markets.
7Alternative Brain Surface Interface
Beyond retinal hardware, Science Corporation develops cranial interfaces designed to rest on the brain rather than penetrating neural tissue. This structural distinction contrasts sharply with invasive architectures like Neuralink. The company targets clinical indications including stroke rehabilitation, brain tumor monitoring, and unannounced neurodegenerative conditions across deep-brain pathways.
8Long-Term Neurological Health Span
Science Corporation positions neurotechnology around extending functional health span rather than recreational consumer interfaces. Executive strategy assumes widespread demographic adoption around ages sixty and seventy as neural degradation occurs. The overarching mission balances commercial therapeutic devices with long-term foundational research into understanding and engineering complex brain circuitry.